A 16-year cohort study compares proteomic organ clocks against epigenetic and physical aging metrics. Learn why traditional functional tests often outperform them.
On October 2, 2026, researchers using data from the University of Edinburgh published a study in Aging Cell that compared plasma proteomic organ clocks against established aging biomarkers.
The analysis concluded that while protein-based organ clocks significantly track with mortality risk, several other types of measurements actually perform better. Within this cohort, older epigenetic age and smaller brain volumes demonstrated stronger mortality associations than the highlighted organ clocks. Reduced respiratory function and poorer cognition also outperformed the protein panels in identifying risk. This research highlights that biological age is not a single interchangeable metric, and different testing domains yield entirely different predictive strengths for human survival.
This observational study was conducted in humans, specifically following older Scottish adults over a 16-year period.
The research team utilized data from 861 participants enrolled in the Lothian Birth Cohort 1936. Investigators monitored these individuals over a 16-year follow-up period to assess how different biological measurements related to survival. During this extensive observation window, the researchers recorded 444 deaths among the studied participants. The team then used Cox regression models to evaluate robust associations between various biomarkers and all-cause mortality.
It is crucial to understand that the study specifically tracked all-cause mortality rather than specific disease outcomes. This broad metric simply records whether a participant died during the follow-up period from any cause. Evaluating all-cause mortality helps researchers determine the general predictive strength of a physiological biomarker. However, an association with all-cause mortality does not establish that a measurement can identify a specific cause of death.
Scientists have increasingly utilized advanced diagnostic panels to estimate the biological ages of multiple internal organs. These specialized tests analyze the distinct patterns of proteins circulating in the bloodstream to evaluate physiological decline. The research team noted a significant gap in the scientific literature regarding these specific measurements. Before this publication, systematic comparisons between proteomic organ clocks and established aging biomarkers were largely lacking.
The researchers successfully identified specific organ-based protein signatures that correlated with a higher risk of death. Accelerated liver, immune, and heart aging showed the strongest reported mortality associations among the organ clocks tested. The calculated hazard ratios were 1.43 for liver aging, 1.42 for immune aging, and 1.38 for heart aging per standard-deviation increase. These figures indicate a measurable relationship between organ-specific protein profiles and overall lifespan within this cohort.
Despite the advanced technology behind proteomic organ clocks, several non-proteomic measures showed stronger mortality associations in this analysis. The researchers evaluated the GrimAge2 epigenetic clock alongside various cognitive and structural assessments. According to news accounts covering the study, GrimAge2 emerged as the strongest individual predictor of mortality. However, the exact individual hazard ratio for this specific epigenetic clock is not detailed in the available research abstract.
The study grouped epigenetic age together with structural and functional measurements to report their overall predictive strength. Smaller total brain and grey-matter volumes demonstrated robust associations with mortality that surpassed the blood-based organ tests. The paper reported a collective hazard-ratio range of 1.44 to 1.62 per standard deviation for these diverse non-organ measurements. This compelling finding suggests that traditional structural brain assessments remain highly valuable for evaluating longevity.
Beyond testing established organ clocks, the researchers conducted a massive screening of individual plasma proteins. The team analyzed 9,703 plasma protein targets to identify novel longevity metrics. From this extensive search, they identified 368 candidate proteins that were actively associated with mortality. Scientists track these molecular shifts to better map cellular health and metabolic changes over extended timeframes.
The researchers pinpointed three specific proteins that exhibited the strongest positive associations with mortality in their screening. GDF15 led the group with a hazard ratio of 1.56. WFDC2 followed closely with a hazard ratio of 1.47, while TIMP1 showed a hazard ratio of 1.45. These individual protein markers provided compelling data points for understanding systemic physiological decline in older adults.
The study provided important clues regarding the biological pathways driving these protein-based mortality associations. The published paper reported that higher-risk proteins were heavily enriched for immune functions. Conversely, the lower-risk proteins were primarily involved in genomic stability and general cellular maintenance. This stark contrast suggests that systemic immune regulation and cellular repair mechanisms heavily influence the human aging process.
Readers must carefully interpret these reported hazard ratios to avoid drawing incorrect personal conclusions. The published hazard ratios describe population-level associations per standard deviation rather than an individual person's absolute probability of death. They should never be read as direct personal predictions or definitive diagnostic forecasts. People seeking to understand longevity science fundamentals should view these metrics as broad risk indicators.
The findings clearly illustrate why biological age should never be treated as a single interchangeable measurement. The study compared measures from entirely different domains, including proteins, DNA methylation, physical function, and brain imaging. Each distinct biological domain demonstrated a different strength of association with human mortality. This variability confirms that no single commercial test can currently diagnose aging or precisely predict an individual lifespan.
The strong performance of respiratory function tests in this study highlights the enduring value of traditional physiological metrics. While molecular tests map cellular changes, functional tests measure how well the body actually performs in the real world. Reduced respiratory capacity demonstrated a formidable association with mortality that rivaled complex epigenetic evaluations. This reality reminds researchers that assessing physical vitality remains a cornerstone of robust longevity research.
Brain imaging and cognitive assessments also proved to be exceptionally powerful tools for predicting mortality within this cohort. Smaller total brain volumes and poorer cognitive performance signaled elevated mortality risks more strongly than several advanced plasma protein panels. These results suggest that structural brain health acts as a critical barometer for overall systemic resilience. Researchers studying emerging longevity therapeutics must ensure their clinical trials account for these vital neurological markers.
Researchers face significant challenges when extrapolating data from a single specialized demographic group. This specific investigation relied entirely on older Scottish adults from a distinct birth year cohort. Scientists cannot assume that these exact biomarker rankings will remain identical when tested in younger demographics. Medical professionals require much more comprehensive testing frameworks before they can confidently apply these findings to general preventative care.
Reducing the complex biological process of aging into a single numerical score often obscures critical medical nuances. When commercial clinics market isolated biological age metrics, they risk oversimplifying profound physiological changes. This detailed comparative study proves that cellular maintenance and immune regulation operate along entirely different biological axes. Patients deserve transparent medical communication that acknowledges the clear limitations of current biomarker technology.
Future longitudinal studies must test these comparative biomarker rankings across younger, globally diverse populations to determine their true clinical utility.
Once researchers document how different biomarker formats predict mortality differently in humans, the next critical step is evaluating which of these tests actually reflect modifiable cellular decline. AgeAmaze solves the persistent difficulty distinguishing animal research from human evidence, ensuring that research-minded adults can accurately interpret complex diagnostic trials without assuming population statistics translate into guaranteed personal outcomes.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
